TNIK Therapeutics Overview
- Year Founded
-
2018
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
TNIK Therapeutics General Information
Description
Developer of small molecule inhibitors designed to target cancer stem cells. The company's inhibitors regulate the beta-catenin TCF4 transcription complex responsible for the activation of genes important for stemness and proliferation, enabling doctors to target cancer stem cell diseases.
Contact Information
Corporate Office
- Ilan Ramon Street 2
- Ness Ziona 7403635
- Israel
Corporate Office
- Ilan Ramon Street 2
- Ness Ziona 7403635
- Israel
TNIK Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 01-Aug-2022 | Completed | Out of Business | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Seed Round | 01-Jan-2019 | Completed | Startup |
TNIK Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TNIK Therapeutics FAQs
-
When was TNIK Therapeutics founded?
TNIK Therapeutics was founded in 2018.
-
Where is TNIK Therapeutics headquartered?
TNIK Therapeutics is headquartered in Ness Ziona, Israel.
-
What industry is TNIK Therapeutics in?
TNIK Therapeutics’s primary industry is Drug Discovery.
-
Is TNIK Therapeutics a private or public company?
TNIK Therapeutics is a Private company.
-
What is TNIK Therapeutics’s current revenue?
The current revenue for TNIK Therapeutics is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
